N-hydroxy-1-phenyl-cyclopropanecarboxamidine | 925252-34-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-hydroxy-1-phenyl-cyclopropanecarboxamidine
• 英文别名: n-Hydroxy-1-phenylcyclopropanecarboximidamide；N'-hydroxy-1-phenylcyclopropane-1-carboximidamide
• CAS: 925252-34-2
• 化学式: C₁₀H₁₂N₂O
• 分子量: 176.218
• InChiKey: QSLURBVCIYBHAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-hydroxy-1-phenyl-cyclopropanecarboxamidine 、 氯乙酰氯 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 3.17h， 生成 [(Z)-[amino-(1-phenylcyclopropyl)methylidene]amino] 2-chloroacetate
  参考文献：
  名称：

  WO2008/50200

  摘要：

  公开号：
• 作为产物：
  描述：

  1-苯基环丙基甲腈 在 盐酸羟胺 、 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 6.0h， 生成 N-hydroxy-1-phenyl-cyclopropanecarboxamidine
  参考文献：
  名称：

  WO2008/50200

  摘要：

  公开号：

文献信息

• [EN] OXADIAZOLE COMPOUNDS<br/>[FR] COMPOSÉS D'OXADIAZOLE
  申请人：REMYND NV

  公开号：WO2015140130A1

  公开（公告）日：2015-09-24

  The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1,R2,R3,L1,L2,L3,L4,L5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.

  本发明涉及式(I)或(II)的化合物或其立体异构体、对映体、消旋体或互变异构体，其中R1、R2、R3、L1、L2、L3、L4、L5和n的含义与权利要求和说明中定义的含义相同。本发明还涉及包含这些化合物的组合物，特别是药物，以及利用这些化合物和组合物预防和/或治疗代谢紊乱和/或神经退行性疾病和/或蛋白质错折性疾病的用途。
• XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS
  申请人：Hatley Richard Jonathan Daniel

  公开号：US20100168122A1

  公开（公告）日：2010-07-01

  The present invention relates to compounds of formula (I) which are xanthine derivatives, processes for manufacture of said derivatives, pharmaceutical formulations containing these compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial

  本发明涉及公式（I）的化合物，它们是黄嘌呤衍生物，制备这些衍生物的过程，含有这些化合物的药物配方以及在治疗中使用这些化合物，例如，在疾病治疗中，HM74A受体的欠活化对疾病有贡献或激活受体将有益的情况下。
• Oxadiazole compounds
  申请人：REMYND NV

  公开号：US10562869B2

  公开（公告）日：2020-02-18

  The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1, R2, R3, L1, L2, L3, L4, L5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.

  本发明涉及式(I)或(II)化合物或其立体异构体、对映体、外消旋体或同系物，(I)(II) 其中R1、R2、R3、L1、L2、L3、L4、L5和n与权利要求和说明中定义的含义相同。本发明还涉及包含此类化合物的组合物，特别是药物，以及此类化合物和组合物在预防和/或治疗代谢紊乱和/或神经退行性疾病和/或蛋白质错误折叠紊乱方面的用途。
• WO2007/62773
  申请人：——

  公开号：——

  公开（公告）日：——
• OXADIAZOLE COMPOUNDS
  申请人：REMYND NV

  公开号：US20170073319A1

  公开（公告）日：2017-03-16

  The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R 1 , R 2 , R 3 , L 1 , L 2 , L 3 , L 4 , L 5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.